Severe hypoglycemia during pneumocystis pneumonia treatment associated with trimethoprim–sulfamethoxazole use in a patient on peritoneal dialysis

Severe hypoglycemia during pneumocystis pneumonia treatment associated with trimethoprim–sulfamethoxazole use in a patient on peritoneal dialysis

Abstract Background Trimethoprim–sulfamethoxazole (TMP/SMX) is an essential antimicrobial agent for treating pneumocystis pneumonia (PCP). Furthermore, the risk of hypoglycemia is increased with the co-administration of sulfonylurea due to the presence of the same sulfanilamide structural group in S...

Full description

Bibliographic Details
Main Authors: Arata Hibi, Yusuke Kuga, Chiharu Ito, Toshiyuki Miura, Satoru Kominato, Keisuke Kamiya, Takahisa Kasugai, Katsushi Koyama
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Renal Replacement Therapy
Subjects:
Trimethoprim–sulfamethoxazole
Hypoglycemia
Pneumocystis pneumonia
Peritoneal dialysis
Online Access:http://link.springer.com/article/10.1186/s41100-017-0125-8

Internet

http://link.springer.com/article/10.1186/s41100-017-0125-8

Similar Items